CL2007002030A1 - Composicion y proceso de preparacion de un biocida libre de solvente que comprende al menos un biocida insoluble en agua y un material portador soluble en agua en forma nano-dispersa con un diametro pico bajo 1000 nm. - Google Patents

Composicion y proceso de preparacion de un biocida libre de solvente que comprende al menos un biocida insoluble en agua y un material portador soluble en agua en forma nano-dispersa con un diametro pico bajo 1000 nm.

Info

Publication number
CL2007002030A1
CL2007002030A1 CL2007002030A CL2007002030A CL2007002030A1 CL 2007002030 A1 CL2007002030 A1 CL 2007002030A1 CL 2007002030 A CL2007002030 A CL 2007002030A CL 2007002030 A CL2007002030 A CL 2007002030A CL 2007002030 A1 CL2007002030 A1 CL 2007002030A1
Authority
CL
Chile
Prior art keywords
biocide
composition
carrier material
nano
preparation process
Prior art date
Application number
CL2007002030A
Other languages
English (en)
Spanish (es)
Inventor
David John Duncalf
Alison Jayne Foster
James Long
Steven Paul Rannard
Dong Wang
Original Assignee
Unilever Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Nv filed Critical Unilever Nv
Publication of CL2007002030A1 publication Critical patent/CL2007002030A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
CL2007002030A 2006-07-13 2007-07-12 Composicion y proceso de preparacion de un biocida libre de solvente que comprende al menos un biocida insoluble en agua y un material portador soluble en agua en forma nano-dispersa con un diametro pico bajo 1000 nm. CL2007002030A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0613925.7A GB0613925D0 (en) 2006-07-13 2006-07-13 Improvements relating to nanodispersions

Publications (1)

Publication Number Publication Date
CL2007002030A1 true CL2007002030A1 (es) 2008-01-18

Family

ID=36955583

Family Applications (4)

Application Number Title Priority Date Filing Date
CL2007002030A CL2007002030A1 (es) 2006-07-13 2007-07-12 Composicion y proceso de preparacion de un biocida libre de solvente que comprende al menos un biocida insoluble en agua y un material portador soluble en agua en forma nano-dispersa con un diametro pico bajo 1000 nm.
CL2007002031A CL2007002031A1 (es) 2006-07-13 2007-07-12 Composicion farmaceutica que comprende una droga antiparasitaria insoluble en agua y un portador soluble en agua, en donde la droga se encuentra en la forma nano-dispersa; dispersion acuosa que la comprende; proceso para prepararla, util para el tratamiento o profilaxis de la malaria.
CL2007002032A CL2007002032A1 (es) 2006-07-13 2007-07-12 Proceso para elaborar nanodispersiones contra solubles de materiales escasamente solubles en un material vehiculo que comprende proveer una mezcla de una unica fase de una mezcla de solventes miscibles,un material vehiculo soluble en el solvente y un material de carga util soluble en el solvente y secar por aspersion la mezcla por remocion del solvente.
CL2010000516A CL2010000516A1 (es) 2006-07-13 2010-05-19 Composicion fungicida sin solvente que comprende estrobirulina insoluble en agua dispersado a traves del material portador en forma nano-dispersa teniendo un diametro pico de la forma nano-dispersa menor a 1000 nm; proceso para preparar dicha composicion; uso de dicha composicion para tratar una infestacion (divisional de la sol. 2030-07).

Family Applications After (3)

Application Number Title Priority Date Filing Date
CL2007002031A CL2007002031A1 (es) 2006-07-13 2007-07-12 Composicion farmaceutica que comprende una droga antiparasitaria insoluble en agua y un portador soluble en agua, en donde la droga se encuentra en la forma nano-dispersa; dispersion acuosa que la comprende; proceso para prepararla, util para el tratamiento o profilaxis de la malaria.
CL2007002032A CL2007002032A1 (es) 2006-07-13 2007-07-12 Proceso para elaborar nanodispersiones contra solubles de materiales escasamente solubles en un material vehiculo que comprende proveer una mezcla de una unica fase de una mezcla de solventes miscibles,un material vehiculo soluble en el solvente y un material de carga util soluble en el solvente y secar por aspersion la mezcla por remocion del solvente.
CL2010000516A CL2010000516A1 (es) 2006-07-13 2010-05-19 Composicion fungicida sin solvente que comprende estrobirulina insoluble en agua dispersado a traves del material portador en forma nano-dispersa teniendo un diametro pico de la forma nano-dispersa menor a 1000 nm; proceso para preparar dicha composicion; uso de dicha composicion para tratar una infestacion (divisional de la sol. 2030-07).

Country Status (17)

Country Link
US (10) US20090175953A1 (enExample)
EP (8) EP2040679A2 (enExample)
JP (9) JP2009542764A (enExample)
CN (11) CN101489535A (enExample)
AP (1) AP2008004713A0 (enExample)
AR (4) AR061992A1 (enExample)
AU (9) AU2007271830B2 (enExample)
BR (8) BRPI0714230A2 (enExample)
CA (8) CA2656229C (enExample)
CL (4) CL2007002030A1 (enExample)
ES (2) ES2741124T3 (enExample)
GB (1) GB0613925D0 (enExample)
IL (2) IL195911A0 (enExample)
MX (2) MX2009000307A (enExample)
TW (1) TW200812694A (enExample)
WO (8) WO2008006714A2 (enExample)
ZA (7) ZA200900029B (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0501833D0 (en) * 2005-01-28 2005-03-09 Unilever Plc Carrier liquids and methods of production thereof
WO2007133758A1 (en) * 2006-05-15 2007-11-22 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
WO2008022651A1 (en) 2006-08-21 2008-02-28 Antoine Turzi Process and device for the preparation of platelet rich plasma for extemporaneous use and combination thereof with skin and bone cells
AR063704A1 (es) 2006-09-14 2009-02-11 Makhteshim Chem Works Ltd Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones
JP2010522135A (ja) 2006-10-09 2010-07-01 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
WO2009047634A2 (en) * 2007-06-18 2009-04-16 Combino Pharm, S.L. Aqueous formulations of acetaminophen for injection
WO2009081283A2 (en) * 2007-06-18 2009-07-02 Combino Pharm, S.L. Aqueous formulations of acetaminophen for injection
PL2200588T3 (pl) 2007-09-25 2019-09-30 Solubest Ltd. Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
TR200800634A2 (tr) * 2008-01-30 2009-02-23 Takka Sevgi̇ Uzatılmış salım sağlayan fluvastatin tablet.
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AU2009223061B2 (en) * 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
KR101376397B1 (ko) * 2008-07-11 2014-03-20 닛뽕소다 가부시키가이샤 서방성 제제 조성물의 제조 방법
GB0814953D0 (en) * 2008-08-18 2008-09-24 Unilever Plc Improvements relating to nanodisperse compositions
EP3378310B1 (en) 2008-09-25 2021-08-04 Vive Crop Protection Inc. Methods to produce polymer nanoparticles and formulations of active ingredients
FR2938433B1 (fr) * 2008-11-19 2011-09-09 Francois Fauran Compositions pharmaceutiques utilisant l'inuline comme excipient de granulation
US8927063B2 (en) * 2008-12-12 2015-01-06 Timtechchem International Limited Compositions for the treatment of timber and other wood substrates
EP2243477A1 (de) 2009-04-22 2010-10-27 Fresenius Kabi Deutschland GmbH Paracetamol zur parenteralen Verabreichung
WO2010137888A2 (ko) * 2009-05-27 2010-12-02 주식회사 삼양사 생체이용률이 향상된 난용성 약물 함유 미립구 및 그 제조 방법
HUP0900376A2 (en) * 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate candesartan cilexetil composition
HUP0900384A2 (en) * 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate olmesartan medoxomil compositions
KR101817986B1 (ko) * 2009-06-25 2018-01-16 진양제약주식회사 카르복시로자탄을 함유하는 약학 조성물 및 이의 제조방법
EP3311667A1 (en) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmaceutical compositions
BR112012004525A2 (pt) * 2009-08-31 2016-03-22 Depomed Inc composição farmacêuticas gástrico-rententivas para liberação imediata ou prolongada de acetaminofeno
JP5498769B2 (ja) * 2009-12-04 2014-05-21 花王株式会社 脂溶性薬物内包ナノ粒子の製造方法
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
SI2536396T1 (sl) 2010-02-16 2017-01-31 KRKA, tovarna zdravil, d.d.,Novo mesto Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
JP5602936B2 (ja) 2010-03-29 2014-10-08 フイルメニツヒ ソシエテ アノニム 噴霧乾燥した結晶性活性成分
GB201006038D0 (en) * 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
UA111167C2 (uk) * 2010-08-05 2016-04-11 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Пестицидні композиції мезорозмірних частинок з підсиленою дією
US20130196852A1 (en) * 2010-10-05 2013-08-01 Iota Nanosolutions Limited Processes for preparing improved compositions
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
US8637038B2 (en) 2011-04-12 2014-01-28 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
JP2013001771A (ja) * 2011-06-14 2013-01-07 Neos Co Ltd 液状カビ防除洗浄剤組成物
RU2469536C1 (ru) * 2011-06-16 2012-12-20 Государственное бюджетное учреждение Республики Башкортостан "Научно-исследовательский технологический институт гербицидов и регуляторов роста растений с опытно-экспериментальным производством Академии наук Республики Башкортостан" Фунгицидное средство и способ его получения
AU2012272804B2 (en) 2011-06-22 2017-07-06 Vyome Therapeutics Limited Conjugate-based antifungal and antibacterial prodrugs
CN104039140B (zh) 2011-08-23 2017-07-21 维弗作物保护公司 拟除虫菊酯配制品
GB201115079D0 (en) 2011-08-31 2011-10-19 Iota Nanosolutions Ltd Method of preparing carrier liquids
GB201115633D0 (en) 2011-09-09 2011-10-26 Univ Liverpool Compositions of efavirenz
GB201115635D0 (en) 2011-09-09 2011-10-26 Univ Liverpool Compositions of lopinavir and ritonavir
GB201115634D0 (en) 2011-09-09 2011-10-26 Univ Liverpool Compositions of lopinavir
US8609684B2 (en) * 2011-12-12 2013-12-17 PruGen IP Holdings, Inc. Solubilization and bioavailability of acetaminophen
EP2793574A4 (en) 2011-12-22 2015-09-02 Vive Crop Prot Inc STROBILURINFORMULIERUNGEN
WO2013172999A1 (en) * 2012-05-16 2013-11-21 Mewa Singh Pharmaceutical compositions for the delivery of substantially water-insoluble drugs
CA2877774C (en) 2012-07-12 2017-07-18 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
US20140073678A1 (en) * 2012-09-12 2014-03-13 Monosol Rx, Llc Anti-pain and anti-nausea and/or vomiting combinatorial compositions
MX2015016675A (es) 2013-06-04 2016-07-15 Vyome Biosciences Pvt Ltd Particulas recubiertas y composiciones que comprenden las mismas.
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
SG11201603134XA (en) 2013-10-21 2016-05-30 Salk Inst For Biological Studi Mutated fibroblast growth factor (fgf) 1 and methods of use
WO2015070396A1 (zh) * 2013-11-13 2015-05-21 财团法人国防教育研究基金会 无肝副作用的对乙酰胺基酚新复方组合
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015134920A1 (en) 2014-03-07 2015-09-11 The Arizona Board Of Regents On Behalf Of The University Of Arizona Non-narcotic crmp2 peptides targeting sodium channels for chronic pain
EP2952208A1 (en) * 2014-06-04 2015-12-09 Universidade de Santiago de Compostela Hydroalcoholic system for nail treatment
MX387735B (es) 2014-06-11 2025-03-11 SpecGx LLC Composiciones secadas por pulverización que tienen diferentes perfiles de disolución y procesos para su preparación.
CN104042626A (zh) * 2014-07-01 2014-09-17 李绍明 杀菌抑菌剂
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3237159B1 (en) * 2014-12-23 2019-05-01 Dow Global Technologies LLC Treated porous material
WO2016116121A1 (en) * 2015-01-20 2016-07-28 Merck Patent Gmbh Solid dispersions of compounds using polyvinyl alcohol as a carrier polymer
CN104798772B (zh) * 2015-03-13 2017-05-24 中国农业科学院农业环境与可持续发展研究所 一种农药纳米固体分散体及其制备方法
EP3316865A4 (en) 2015-07-02 2019-01-23 Civitas Therapeutics, Inc. TRIPTAN POWDER FOR PULMONARY ADMINISTRATION
ES2952606T3 (es) * 2015-07-17 2023-11-02 Univ Oklahoma Derivados de licofelona y métodos de uso
CN105145553A (zh) * 2015-10-12 2015-12-16 广西田园生化股份有限公司 一种难溶农药的固体分散体组合物
CN108601342A (zh) * 2016-02-02 2018-09-28 赢创德固赛有限公司 在固体水溶性载体上具有表面活性物质的粉末状配制物、其生产方法和其用途
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
CA3027817C (en) 2016-06-16 2023-12-19 The University Of Liverpool Chemical composition for the treatment and prophylaxis of systemic infections
RU2619249C1 (ru) * 2016-11-07 2017-05-12 Федеральное государственное бюджетное учреждение науки Институт химии твердого тела и механохимии Сибирского отделения Российской академии наук (ИХТТМ СО РАН) Композиция для протравливания семян и способ её получения
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis
CN110741009A (zh) 2017-03-31 2020-01-31 利物浦大学 前药组合物
WO2018232053A2 (en) * 2017-06-15 2018-12-20 Savior Lifetec Corporation Methods for producing particles of an active ingredient
EP3672411A4 (en) 2017-08-25 2021-05-19 Vive Crop Protection Inc. MULTI-COMPONENT, SOIL APPLICABLE PESTICIDAL COMPOSITIONS
WO2019166834A1 (en) 2018-03-02 2019-09-06 The University Of Liverpool Solid compositions of actives, processes for preparing same and uses of such solid compositions
JP6858729B2 (ja) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
CA3114911A1 (en) 2018-10-04 2020-04-09 Rutgers, The State University Of New Jersey Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides
WO2020135600A1 (zh) * 2018-12-28 2020-07-02 南京善思生物科技有限公司 纳米农药制剂及其制备方法
CN109846821B (zh) * 2019-01-03 2021-07-06 昆药集团股份有限公司 一种蒿甲醚纳米制剂及其制备方法
WO2020186187A1 (en) 2019-03-13 2020-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
CN110074993A (zh) * 2019-06-05 2019-08-02 山东大学 一种制备紫外吸收剂纳米颗粒的方法
MX2021015576A (es) * 2019-06-28 2022-03-02 Solstar Pharma Formulacion gastroretentiva de liberacion extendida contra helicobacter pylori.
WO2021062012A1 (en) 2019-09-25 2021-04-01 Emory University Use of klk10 and engineered derivatizations thereof
CN114615889A (zh) * 2019-10-28 2022-06-10 组合化学工业株式会社 农药组合物及其制造方法
AU2021208631A1 (en) 2020-01-17 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene therapy for treatment of CRX-autosomal dominant retinopathies
WO2021225781A2 (en) 2020-05-07 2021-11-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
IT202000022789A1 (it) 2020-09-28 2020-12-28 Vitop Moulding Srl Rubinetto erogatore provvisto di sistema di collocamento, bloccaggio e orientamento su scatole di tipo Bag-In-Box
GB202115049D0 (en) 2021-10-20 2021-12-01 Univ Liverpool Chemical Compositions
WO2023196898A1 (en) 2022-04-07 2023-10-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta globin mimetic peptides and their use
CN114732009B (zh) * 2022-06-13 2022-08-23 山东百农思达生物科技有限公司 一种含有吡唑醚菌酯和烯酰吗啉的水分散粒剂的制备方法
AU2024240009A1 (en) 2023-03-17 2025-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treatment of age-related macular degeneration
GB202304657D0 (en) 2023-03-29 2023-05-10 Univ Liverpool Atovaquine compositions

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB501835A (en) 1936-05-29 1939-03-02 Siemens Ag Process and apparatus for reducing the power required for the mechanical treatment of movable masses
GB1305024A (enExample) * 1969-07-10 1973-01-31
GB1554662A (en) * 1976-05-05 1979-10-24 Inverni Della Beffa Spa Polyhydroxyphenylchromanones
US4230687A (en) * 1978-05-30 1980-10-28 Griffith Laboratories U.S.A., Inc. Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices
DE3439482A1 (de) * 1984-10-27 1986-05-07 Röhm GmbH, 6100 Darmstadt Verfahren zur beschichtung von substraten mit kratzfesten, nichtreflektierenden ueberzuegen
US4830858A (en) * 1985-02-11 1989-05-16 E. R. Squibb & Sons, Inc. Spray-drying method for preparing liposomes and products produced thereby
US5160530A (en) * 1989-01-24 1992-11-03 Griffin Corporation Microencapsulated polymorphic agriculturally active material
GB8918807D0 (en) * 1989-08-17 1989-09-27 Shell Int Research A solid pesticidal formulation,a process for its preparation and the use thereof
JP3067810B2 (ja) * 1990-12-21 2000-07-24 中外製薬株式会社 経口投与用ｏ／ｗ型エマルジョンの乾燥粉末製造法
GB9304294D0 (en) * 1993-03-03 1993-04-21 Zeneca Ltd Herbicidal compositions
DE4329446A1 (de) * 1993-09-01 1995-03-02 Basf Ag Verfahren zur Herstellung von feinteiligen Farb- oder Wirkstoffzubereitungen
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
TW318777B (enExample) * 1995-06-29 1997-11-01 Novartis Ag
WO1997013503A1 (en) 1995-10-13 1997-04-17 The Penn State Research Foundation Synthesis of drug nanoparticles by spray drying
GB9606188D0 (en) 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
US5858409A (en) * 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
WO1998029141A1 (en) * 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
JP4183279B2 (ja) * 1997-04-15 2008-11-19 アール ピー シェーラー テクノロジーズ インコーポレーテッド 医薬用加水分解セルロース顆粒
WO1999044594A1 (fr) * 1998-03-05 1999-09-10 Nippon Shinyaku Co., Ltd. Emulsions huileuses destinees a etre administrees par inhalation
JPH11322587A (ja) 1998-05-18 1999-11-24 Sumitomo Chem Co Ltd 常温で固体の生理活性物質のマイクロカプセル化方法およびこの方法により得られるマイクロカプセル組成物
WO2000040220A1 (en) * 1999-01-06 2000-07-13 Korea Research Institute Of Chemical Technology Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same
DE60039379D1 (de) * 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
GB9904012D0 (en) 1999-02-22 1999-04-14 Zeneca Ltd Agrochemical formulation
HK1048956B (zh) * 1999-05-27 2006-07-28 阿库斯菲尔公司 多孔药物基质及其制造方法
US7919119B2 (en) 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
GB9920148D0 (en) * 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel composition
WO2001039836A1 (en) 1999-12-01 2001-06-07 Natco Pharma Limited A rapid acting freeze dired oral pharmaceutical composition for treating migraine
KR100694667B1 (ko) * 1999-12-08 2007-03-14 동아제약주식회사 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제
US6207674B1 (en) * 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US20020044969A1 (en) 2000-05-22 2002-04-18 Jerome Harden Method for increasing the compressibility of poorly binding powder materials
US6932963B2 (en) * 2000-06-23 2005-08-23 Nicholas V. Perricone Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines
IT1318618B1 (it) 2000-07-10 2003-08-27 A C R Applied Coating Res S A Microsfere bioadesive a rilascio rapido per la somministrazionesublinguale di principi attivi.
AU2002224526A1 (en) * 2000-07-24 2002-02-05 Ono Pharmaceutical Co. Ltd. Freeze-dried preparation of n-(o-(p-pivaloyloxybenzenesulfonylamino)benzoyl)glycine monosodium salt tetrahydrate and process for producing the same
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
NZ525306A (en) * 2000-09-20 2004-11-26 Skyepharma Canada Inc Spray drying process and compositions of fenofibrate
US6756062B2 (en) * 2000-11-03 2004-06-29 Board Of Regents University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
CA2436418A1 (en) * 2001-01-30 2002-08-08 Board Of Regents, The University Of Texas Systems Process for production of nanoparticles and microparticles by spray freezing into liquid
US6355675B1 (en) 2001-05-15 2002-03-12 Isp Investments Inc. Emulsifiable concentrate of a water-insoluble fungicide
PT1411900E (pt) 2001-06-01 2010-10-11 Pozen Inc Composições farmacêuticas para a entrega coordenada de aines
SK15732003A3 (sk) * 2001-06-22 2005-01-03 Pfizer Products Inc. Farmaceutické kompozície zahrnujúce liečivá s nízkou rozpustnosťou a/alebo liečivá citlivé na kyselinu a neutralizované kyslé polyméry
KR100425226B1 (ko) * 2001-07-03 2004-03-30 주식회사 팜트리 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법
US7836477B2 (en) * 2001-08-21 2010-11-16 Sony Corporation Information processing system, information processing apparatus and method
WO2003026611A2 (en) 2001-09-26 2003-04-03 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
DE10151392A1 (de) * 2001-10-18 2003-05-08 Bayer Cropscience Ag Pulverförmige Feststoff-Formulierungen
US20040266626A1 (en) * 2001-11-07 2004-12-30 Wolfgang Schrof Solid crop protection formulations and dispersion formulations and their use in agriculture
EP1443819A1 (en) * 2001-11-07 2004-08-11 Basf Aktiengesellschaft Solid crop protection formulations containing cinidon-ethyl, and corresponding dispersions
EP1474144B1 (en) * 2002-02-01 2008-08-06 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
IL162819A0 (en) * 2002-02-01 2005-11-20 Pfizer Prod Inc Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
US20040028505A1 (en) * 2002-06-07 2004-02-12 Bilbrey Robert A. Document tape binding system with automatic tape feed, tape indicia sensing, spine printing method and post-bind automation mechanisms
CA2488499C (en) 2002-06-10 2013-03-19 Elan Pharma International Ltd. Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"),combinations thereof as well as manufacturing of these pharmaceutical compositions
US20030017208A1 (en) * 2002-07-19 2003-01-23 Francis Ignatious Electrospun pharmaceutical compositions
DE10244681A1 (de) 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
AU2003268380A1 (en) * 2002-10-04 2004-05-04 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
CN1176649C (zh) 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
AU2003304108B2 (en) * 2002-10-30 2007-03-22 Spherics, Inc. Nanoparticulate bioactive agents
AU2003303631B2 (en) * 2002-12-26 2008-05-29 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Multilayer Dosage Forms Containing NSAIDs and Triptans
US8034378B2 (en) * 2002-12-27 2011-10-11 Novartis Vaccines And Diagnostics, Inc Immunogenic compositions containing phospholipid
AU2004206109A1 (en) * 2003-01-21 2004-08-05 Ranbaxy Laboratories Limited Co-precipitated amorphous losartan and dosage forms comprising the same
US20040197301A1 (en) * 2003-02-18 2004-10-07 Zhong Zhao Hybrid polymers and methods of making the same
JP2006523620A (ja) * 2003-02-19 2006-10-19 バイオヴェイル ラボラトリーズ インコーポレイテッド 急速吸収選択的５−ｈｔ作用剤製剤
WO2004075921A1 (en) * 2003-02-26 2004-09-10 Vrije Universiteit Brussel Inclusion complex of artemisinin or derivates thereof with cyclodextrins
CA2521420A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
CA2465565A1 (en) 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
CA2532450C (en) * 2003-07-16 2012-09-11 Boehringer Ingelheim International Gmbh Chlorthalidone combinations
US7687167B2 (en) * 2003-07-18 2010-03-30 Panasonic Corporation Power supply unit
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10351004A1 (de) * 2003-10-30 2005-05-25 Basf Ag Nanopartikuläre Wirkstoffformulierungen
DE10351087A1 (de) * 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
KR100603974B1 (ko) * 2003-12-05 2006-07-25 김갑식 고체상 지질을 용매로 이용한 나노수준의 또는 비결정질입자의 제조 방법
DE602004031767D1 (de) * 2003-12-31 2011-04-21 Bend Res Inc Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
IL160095A0 (en) * 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
JP2005298347A (ja) * 2004-04-06 2005-10-27 Yoshiaki Kawashima 吸入製剤及びその製造方法
KR100598326B1 (ko) * 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
MXPA06012251A (es) * 2004-04-28 2006-12-15 Unilever Nv Aceite comestible que comprende estatinas.
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
DE602005019509D1 (de) 2004-06-01 2010-04-08 Teva Gyogyszergyar Zartkoeruen Verfahren für die zubereitung der amorphen form eines medikamentes
DE102004031298A1 (de) 2004-06-28 2006-01-12 Basf Ag Wässrige Dispersionen schwer wasserlöslicher oder wasserunlöslicher Wirkstoffe und daraus hergestellte Trockenpulver enthaltend mindestens ein Polyethergruppen enthaltendes Polymer als Schutzkolloid
AU2005290583A1 (en) * 2004-10-01 2006-04-13 Eisai R & D Management Co., Ltd. Fine particles-containing composition and manufacturing method therefor
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
MX2007008212A (es) * 2005-01-06 2007-08-16 Elan Pharma Int Ltd Formulaciones de candesartan en nanoparticulas.
GB0501835D0 (en) * 2005-01-28 2005-03-09 Unilever Plc Improvements relating to spray dried compositions
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof

Also Published As

Publication number Publication date
WO2008006714A3 (en) 2008-02-21
EP2386292A1 (en) 2011-11-16
ZA200900028B (en) 2010-04-28
CN101489535A (zh) 2009-07-22
CN101489533A (zh) 2009-07-22
CN102671585A (zh) 2012-09-19
IL195911A0 (en) 2009-09-01
IL195933A (en) 2013-06-27
WO2008007151A2 (en) 2008-01-17
BRPI0714179A2 (pt) 2012-12-25
MX2009000307A (es) 2009-01-26
EP2387992A1 (en) 2011-11-23
US20100008995A1 (en) 2010-01-14
AR061990A1 (es) 2008-08-10
US20120134940A1 (en) 2012-05-31
CN101489531A (zh) 2009-07-22
CN101516340A (zh) 2009-08-26
AR077195A2 (es) 2011-08-10
ES2741124T3 (es) 2020-02-10
JP2009542794A (ja) 2009-12-03
CA2656223A1 (en) 2008-01-17
AU2007274040A1 (en) 2008-01-17
CA2657582A1 (en) 2008-01-17
CL2007002032A1 (es) 2008-01-18
US8945626B2 (en) 2015-02-03
JP2009542763A (ja) 2009-12-03
US8821932B2 (en) 2014-09-02
AU2007271828A1 (en) 2008-01-17
CN101489532A (zh) 2009-07-22
WO2008006712A2 (en) 2008-01-17
BRPI0714230A2 (pt) 2013-01-15
AU2007271828B2 (en) 2010-12-02
ZA200900029B (en) 2010-04-28
AR061991A1 (es) 2008-08-10
CN101489534A (zh) 2009-07-22
ES2752460T3 (es) 2020-04-06
WO2008006713A2 (en) 2008-01-17
JP2009542760A (ja) 2009-12-03
CA2656229C (en) 2014-05-27
CL2007002031A1 (es) 2008-01-18
ZA200900027B (en) 2010-04-28
WO2008006712A3 (en) 2009-02-26
EP2040680A2 (en) 2009-04-01
AU2007271827B2 (en) 2010-10-14
WO2008007152A2 (en) 2008-01-17
BRPI0714351A2 (pt) 2013-03-19
AU2007271827A1 (en) 2008-01-17
US20100015229A1 (en) 2010-01-21
CA2659666A1 (en) 2008-01-17
WO2008007151A3 (en) 2008-03-06
WO2008006715A3 (en) 2008-05-08
EP2040678A2 (en) 2009-04-01
US9060937B2 (en) 2015-06-23
AU2007271831B2 (en) 2010-11-18
US20120135058A1 (en) 2012-05-31
ZA200900345B (en) 2010-05-26
MX2009000309A (es) 2009-01-26
AU2007274041A1 (en) 2008-01-17
AU2007271829A1 (en) 2008-01-17
WO2008007150A1 (en) 2008-01-17
WO2008007152A3 (en) 2008-03-06
US7691873B2 (en) 2010-04-06
BRPI0714176A2 (pt) 2012-12-25
WO2008006713A3 (en) 2008-07-31
CA2656233A1 (en) 2008-01-17
EP2269581A1 (en) 2011-01-05
WO2008006714A2 (en) 2008-01-17
CN101516341A (zh) 2009-08-26
CN102631874A (zh) 2012-08-15
EP2040677A2 (en) 2009-04-01
ZA200900030B (en) 2010-04-28
WO2008006716A2 (en) 2008-01-17
BRPI0714177A2 (pt) 2011-05-03
AU2007271830A1 (en) 2008-01-17
AR061992A1 (es) 2008-08-10
JP2009542762A (ja) 2009-12-03
US20090304806A1 (en) 2009-12-10
JP2010202665A (ja) 2010-09-16
AU2010201900A1 (en) 2010-06-03
US20090239749A1 (en) 2009-09-24
EP2040677B1 (en) 2019-05-08
CA2656217A1 (en) 2008-01-17
CN101849911A (zh) 2010-10-06
JP2009542793A (ja) 2009-12-03
CA2656229A1 (en) 2008-01-17
US20100015233A1 (en) 2010-01-21
AU2007271830B2 (en) 2010-11-11
US20100068282A1 (en) 2010-03-18
ZA200900031B (en) 2010-04-28
EP2040681A2 (en) 2009-04-01
BRPI0714353A2 (pt) 2013-05-07
EP2040681B1 (en) 2017-08-09
JP2009542764A (ja) 2009-12-03
EP2040680B1 (en) 2019-08-07
WO2008006715A2 (en) 2008-01-17
US20090325995A1 (en) 2009-12-31
WO2008006716A3 (en) 2008-03-13
CL2010000516A1 (es) 2010-10-15
BRPI0714352A2 (pt) 2013-03-19
EP2040679A2 (en) 2009-04-01
US20090175953A1 (en) 2009-07-09
GB0613925D0 (en) 2006-08-23
AU2007271831A1 (en) 2008-01-17
CN101516342A (zh) 2009-08-26
AU2007274039A1 (en) 2008-01-17
JP2009542761A (ja) 2009-12-03
CA2657586A1 (en) 2008-01-17
CA2657548A1 (en) 2008-01-17
AP2008004713A0 (en) 2008-12-31
ZA200900347B (en) 2010-04-28
BRPI0722376A2 (pt) 2012-05-22
IL195933A0 (en) 2009-09-01
AU2007271829B2 (en) 2011-10-27
TW200812694A (en) 2008-03-16
JP2009542795A (ja) 2009-12-03

Similar Documents

Publication Publication Date Title
CL2007002030A1 (es) Composicion y proceso de preparacion de un biocida libre de solvente que comprende al menos un biocida insoluble en agua y un material portador soluble en agua en forma nano-dispersa con un diametro pico bajo 1000 nm.
ES2665917T3 (es) Endoxifeno para su uso en el tratamiento del cáncer
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
CL2008001749A1 (es) Formulacion acuosa para el tratamiento de materiales no vivientes que comprende un plaguicida, un aglutinante polimerico y agua o mezcla acuosa de disolventes; su procedimiento de preparacion; procedimiento para preparar materiales no vivientes con plaguicida; material no viviente impregnado; y uso de dicho material.
CL2008000510A1 (es) Compuestos conjugados farmaco-ligandos, que se unen a citotoxinas potentes; composicion farmaceutica; y uso para retardar o detener el crecimiento de un tumor en un mamifero.
AR085854A1 (es) Composiciones con forma para suministro uniforme de un agente funcional
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
CO6321254A2 (es) Pirimidin -5-carboxamidas sustituidas 281
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
CR11478A (es) Toalla para llevar puesta
HN2008001720A (es) Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
CR11772A (es) Metodos y composicion liquidas de limpieza
MX388787B (es) El uso de amisulpride como un anti-emético.
AR067227A1 (es) Composicion de tratamiento liquida
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
CL2011000135A1 (es) Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.
CL2010001651A1 (es) Proceso para la obtencion de compuestos de cobre nanoparticulados de superficie modificada que comprende mezclar dos soluciones, una que contiene iones de cobre y otra que contiene al menos un anion, en donde al menos una de ellas contiene un polimero soluble en agua; compuestos de cobre y su uso; y proceso para preparar dispersiones acuosas.
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
BRPI0818808A2 (pt) Composição aquosa herbicida, processo para preparar a mesma, e, mistura.
ECSP088889A (es) Forma nueva de administración de racecadotril
CR11859A (es) Composición y proceso-356
BR112013013117A2 (pt) agente hidrotrópico, uso do mesmo para tornar solúveis tensoativos não iônicos e composições contendo os mesmos
CL2008001072A1 (es) Bloque de limpieza de inodoro que es al menos parcialmente transparente o translucida, que comprende 2 - 50% de material biocida y 50 - 98% de composicion portadora que comprende 5 - 50% de agente jabon, 30 - 90% de humectante, 5 - 30% de solvente; metodo para proporcionar higiene en un inodoro; y uso del bloque
CL2013000994A1 (es) Uso de agente quelante y compuestos antimicrobianos de peptido porque sirve para inhibir el crecimiento de y/o matar un microorganismo patógeno vegetal en una planta; composicion que comprende agente quelante y un agente antimicrobiano.
CR9364A (es) Agentes endoparasiticidas